Hedgehog pathway inhibition and the race against tumor evolution

Dependence of basal cell carcinomas and medulloblastomas on the Hedgehog pathway provides an opportunity for targeted or “personalized” therapy. The recent effectiveness and FDA approval of the first Smoothened inhibitors validates this class of agents, but has revealed drug-resistant tumor variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Atwood, Scott X., Chang, Anne Lynn S., Oro, Anthony E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2012
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471227/
https://www.ncbi.nlm.nih.gov/pubmed/23071148
http://dx.doi.org/10.1083/jcb.201207140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471227/
https://www.ncbi.nlm.nih.gov/pubmed/23071148
http://dx.doi.org/10.1083/jcb.201207140

Ejemplares similares